

# Manage a Product Target

## Learning Objectives

After completing this unit, you'll be able to:


- Identify the main fields on a 'Product Target' record for Portfolio and API sourcing
- Learn about standard 'List Views' and 'Inline Editing' within NextPipe

## Fields to Complete on the Product Target

Haru and Salma will now work closely together to fill all the required fields.

We will use Novartis colors to help demonstrate which role is responsible in the following screenshots for the respective fields. Haru is represented by the orange (Sienna) color and Salma is represented by the blue (Novartis blue) color.

Here is our color code:



We have also placed “Portfolio” and “API sourcing” in the title where their input is required. The applicable sections for Portfolio and API sourcing are **General Details, Selection Review Criteria, Key Dates, Early Stage Details, Clinical Assessment, Polymorph Screening, and API & FDF**.

Global Medical will also act as a support function to complete the clinical fields (annotated in our regular color).

Haru and Salma will now begin the process of completing these fields with the correct values in unison to continue with the Product Target. Let's get started!



You can view the descriptions within SANITY by hovering over the information “i” button.

### General Details (Portfolio & API Sourcing)

1. **Product Target full Name, Product Target Name, Originator Company, Originator Product Name, Pharm compound number, and Product Type**
2. **Originator Product Logo, Therapeutic Area, ATC1, and ATC 3**
3. **RX/GX** - A legal check regarding potential conflicts, here you can select “Yes” or “No”
4. **Category**
5. **Product Comment**

Product Target	
Acetylsalicylic	
Originator Company	Therapeutic Area
	CVM
Product Type	Strengths
Small Molecule	100 mg, 80 mg

Details	
Product Target full Name	Originator Product Logo
Product Target Name	Therapeutic Area
Originator Company	CVM
Originator Product Name	ATC1
Pharm. compound number	B (Blood & Blood Forming Organs)
Product Type	ATC3
Small Molecule	B01C (Platelet Aggregation Inhibitors)
RX/GX	SPIRIT Product ID
Medical Device	BEAT ID
Product Comment	Category
	Global Patent Attorney

## Selection Review Criteria (Portfolio & API Sourcing)

6. **Highest originator development phase, Country of Highest Orig Dev phase, and Monitor the product**
7. **Regulatory Designations, WW Peak Innovator Sales, Year of Peak Innovator sales, and Reference for Innovator Sales**
8. **Ox global Sales Forecast** - Forecast for Rx molecule extracted from various databases (e.g. Evaluate, ADIS, Cortellis, BioMedTracker)

The screenshot shows a form titled "Selection Review Criteria". It contains several rows of criteria, each with an information icon (i) and a pencil icon (✎). A red box labeled "6" highlights the first three rows: "Highest originator development phase", "Country of Highest Orig Dev phase", and "Monitor this Product" (which has a checkbox). A red box labeled "7" highlights the next three rows: "Regulatory Designations", "WW Peak Innovator Sales", "Year of Peak Innovator Sales", and "Reference for Innovator Sales". A blue box labeled "8" highlights the last row: "Ox Global Sales Forecast".

Selection Review Criteria	
Highest originator development phase	<i>i</i>
Country of Highest Orig Dev phase	<i>i</i>
Monitor this Product	<i>i</i> <input type="checkbox"/>
Exclude from Pipeline Screening	<i>i</i> <input type="checkbox"/>
Innovator Sales Threshold Criteria Met	<i>i</i> <input type="checkbox"/>
Regulatory Designations	<i>i</i>
WW Peak Innovator Sales	<i>i</i>
Year of Peak Innovator Sales	<i>i</i>
Reference for Innovator Sales	<i>i</i>
Ox Global Sales Forecast	<i>i</i>

## Key Dates (API Sourcing)

9. **Earliest Gx submission US, and Earliest Gx submission US Status**

The screenshot shows a form titled "Key Dates". It contains several rows of criteria, each with an information icon (i) and a pencil icon (✎). A blue box labeled "9" highlights the first two rows: "Earliest Gx submission US" and "Earliest Gx submission US Status".

Key Dates	
Earliest Gx submission US	<i>i</i>
Earliest Gx submission US Status	<i>i</i>
LoE date US	<i>i</i>
LoE date DE	<i>i</i>
Earliest Gx Regulatory Submission	<i>i</i>
Regulatory Date Status	<i>i</i>
Earliest LoE Date (Sandoz Calculated)	<i>i</i>

## Early Stage Details (API Sourcing & Global Medical)

10. **First decision date, Molecule Assessment, PD Strategy Comment, Technical Complexity API, Technology Details API, Technical Complexity FDF, Technology Details FDF, In-house (PD) Technology available, Target Status** - Process to show the status of API Sourcing & Pre-Screening Activities. Options include: None, New, Assessment, Polymorph Screening, Pre-Dev, Selection, and Decision. **PD strategy** options include: None, RLD similar, API patent circumvention, FDF patent circumvention, and API and FDF Patent circumvention.

11. **Pre Selection Process, Opportunity Priority, Molecule Assessment end date, Pre-development Status, prelim. OEL in  $\mu\text{g}/\text{m}^3$ , API Availability Overview, Potential Suppliers, API Comments, and In-house (Tech Ops) Technology available**
12. **Global Medical / Clinical Groups (Support function)**

Early Stage Details

Target Status

First Decision Date

Molecule Assessment

PD Strategy

PD Strategy Comment

Technical Complexity API

Technology Details API

Technical Complexity FDF

Technology Details FDF

In-house (PD) Technology available

IP Executive Summary

Clinical Complexity

10

Pre Selection Process

Opportunity Priority

Molecule Assessment end date

Development Complexity

Pre-Development status

prelim. OEL in  $\mu\text{g}/\text{m}^3$

API Availability Overview

Potential Suppliers

API Comments

In-house (Tech Ops) Technology available

Clinical complexity remarks

11

12

### Polymorph Screening (API Sourcing)

13. **Polymorphism Screening Status, Polymorphism screening Start date, Polymorphism screening end date, Polymorphism screening comment, and Sandoz Own IP, Polymorphism screening outcome** options: “None”, “No Alternative form found”, “Alternative form”, Alternative salt”, and “Co-crystal”.

Polymorph Screening

Polymorphism Screening Status

Polymorph screening Start date

Polymorphism screening comment

Sandoz Own IP

Polymorphism screening outcome

Polymorph screening End date

13

### API & FDF (Portfolio)

14. **Strengths, Product Dosage Broad, and Product Dosage Form**

API & FDF	
Product Core Substance 1	Acetylsalicylic
Product Core Substance 2	
Product Core Substance 3	
Product Core Substance 4	
Product Core Substance 5	
Product Core Substance 6	
Product Core Substance 7	
	Strengths 100 mg, 80 mg
	Product Dosage Broad Ir oral solid
	Product Dosage Form FCT - TABLET, FILM-COATED
	Supply Conditions (Reference Product)
	Product Core Substance 8
	Product Core Substance 9
	Product Core Substance 10

14

Haru and Salma have successfully completed their responsible fields, let's congratulate them!

You might have noticed that a few fields have been automatically completed such as **SPiRiT Product ID**, **Earliest Gx Reg submission**, and **Earliest LoE Date (Sandoz calculated)**. You can also see that a few important fields have even been left empty such as **API Availability Overview**, **Potential Suppliers**, and **API** comments which are completed by the Sourcing team while **Global Patent Attorney** is solely done by the IP team.

Haru and Salma can easily obtain those necessary details but are not the ones to supply the information themselves.

Great, all the fields have now been completed on the product target through their great collaboration!

## Related List Quick Links

At the bottom of the "Product Target" record, you can find all the relevant links (e.g. to an already created Opp DD) for this Product that are supportive of the evaluation.

Related List Quick Links				
<a href="#">Portfolio Projects (0)</a>	<a href="#">Opportunity Detail &amp; Diligences (2)</a>	<a href="#">Forecasts and Actuals (Product Target (Sandoz Forecast)) (0)</a>	<a href="#">Forecasts and Actuals (0)</a>	<a href="#">Meeting Agenda Items (0)</a>
<a href="#">BEAT Countries (0)</a>	<a href="#">Sandoz SKU (0)</a>	<a href="#">Regulatory Approvals (0)</a>	<a href="#">Product Details (0)</a>	<a href="#">Country Default LoE Dates (0)</a>
<a href="#">Product Target Related Patents (0)</a>	<a href="#">Indications (0)</a>	<a href="#">Product Target History (0)</a>	<a href="#">Files (0)</a>	
<a href="#">Show Less</a>				

As you can see, the "Product Target" record is the starting point of your evaluation and provides all the relevant fields related to timing and product categorization for you to start planning your


selections for Sandoz Pipeline.

Now an “Opportunity Detail & Diligence” record can be created by the Global Portfolio Manager.

## List Views in NextPipe


There are many standard List Views in Nextpipe that are divided by category, some of the most relevant for you to know is the following: **Molecular Assessment Definition, Molecular Assessment Input, Molecular Assessment Input Technology, Product Priority, Polymorphic Screening Status**, and **Product Sourcing**

Here you can see the available standard List views and their corresponding filters/parameters:



You can also use inline editing to update multiple record fields without accessing them one by one, let's save you some time and utilize this incredible feature in SANITY:

1. Access filters
2. Create a new filter by setting the field to Record Type (Required to use inline editing)
3. Hover your mouse over a field and click on the Pencil icon to edit (The lock icon signifies the field can't be edited)
4. Save your changes and you have successfully used Inline editing



If you experience any blockers trying to use inline editing then you should check out the [List Views in SANITY](https://sanity.my.trailhead.com/content/sanity/modules/szsanitym0005rl) (<https://sanity.my.trailhead.com/content/sanity/modules/szsanitym0005rl>) module where we go into greater detail and you can even learn how to create user-specific List Views.

Haru and Salma have successfully completed all the required fields on the Product Target through their focus and wonderful collaboration. You will continue to follow Haru in the next module as he once again works together with Helena from Global Portfolio Governance, Process and Systems to create and fill an Opportunity Detail & Diligence (Opp D&D).

Let's keep this excellent pace and continue to the next module!

## Resources

[List Views in SANITY](https://sanity.my.trailhead.com/content/sanity/modules/szsanitym0005rl) (<https://sanity.my.trailhead.com/content/sanity/modules/szsanitym0005rl>)